xeroderma pigmentosum group G
diseaseOn this page
Also known as ERCC5 xeroderma pigmentosumxeroderma pigmentosum caused by mutation in ERCC5xeroderma pigmentosum complementation group Gxeroderma pigmentosum group type Gxeroderma pigmentosum type 7xeroderma pigmentosum, complementation group Gxeroderma pigmentosum, complementation group type Gxeroderma pigmentosum, group Gxeroderma pigmentosum, group G/Cockayne syndromeXP-GXP7XPG
Summary
xeroderma pigmentosum group G (MONDO:0010216) is a disease caused by ERCC5 (GenCC Definitive), with 2 cohort genes.
At a glance
- Causal gene: ERCC5 (GenCC Definitive)
- Cohort genes: 2
- ClinVar variants: 161
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | xeroderma pigmentosum group G |
| Mondo ID | MONDO:0010216 |
| MeSH | C562593 |
| OMIM | 278780 |
| Orphanet | 276267 |
| DOID | DOID:0110849 |
| NCIT | C3969 |
| SNOMED CT | 36454001 |
| UMLS | C0268141 |
| MedGen | 75657 |
| GARD | 0005629 |
| Is cancer (heuristic) | no |
Also known as: ERCC5 xeroderma pigmentosum · xeroderma pigmentosum caused by mutation in ERCC5 · xeroderma pigmentosum complementation group G · xeroderma pigmentosum group G · xeroderma pigmentosum group type G · xeroderma pigmentosum type 7 · xeroderma pigmentosum, complementation group G · xeroderma pigmentosum, complementation group type G · xeroderma pigmentosum, group G · xeroderma pigmentosum, group G/Cockayne syndrome · XP-G · XP7 · XPG
Data availability: 161 ClinVar variants · 6 GenCC gene-disease records · 30 cell lines.
Disease family
Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › autosomal genetic disease › autosomal recessive disease › COFS syndrome › xeroderma pigmentosum group G
Related subtypes (4): cerebrooculofacioskeletal syndrome 1, cerebrooculofacioskeletal syndrome 2, cerebrooculofacioskeletal syndrome 4, cerebrooculofacioskeletal syndrome 3
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
161 retrieved; paginated sample, class counts are floors:
61 uncertain significance, 38 conflicting classifications of pathogenicity, 18 benign, 15 benign/likely benign, 15 likely pathogenic, 9 pathogenic, 5 pathogenic/likely pathogenic
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 1335951 | NM_000123.4(ERCC5):c.673-2A>G | BIVM-ERCC5 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 16566 | NM_000123.4(ERCC5):c.2878G>T (p.Glu960Ter) | BIVM-ERCC5 | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 16573 | NM_000123.4(ERCC5):c.2573T>C (p.Leu858Pro) | BIVM-ERCC5 | Pathogenic | no assertion criteria provided |
| 16574 | NM_000123.4(ERCC5):c.1115_1118del (p.Arg372fs) | BIVM-ERCC5 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 16575 | NM_000123.4(ERCC5):c.1494del (p.Asp499fs) | BIVM-ERCC5 | Pathogenic | no assertion criteria provided |
| 16576 | NM_000123.4(ERCC5):c.2751del (p.Lys917fs) | BIVM-ERCC5 | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 16578 | NM_000123.4(ERCC5):c.406C>T (p.Gln136Ter) | BIVM-ERCC5 | Pathogenic | no assertion criteria provided |
| 3064167 | NM_000123.4(ERCC5):c.205C>T (p.Arg69Ter) | BIVM-ERCC5 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 3575647 | NM_000123.4(ERCC5):c.410_411dup (p.Arg138fs) | BIVM-ERCC5 | Pathogenic | criteria provided, single submitter |
| 3575661 | NM_000123.4(ERCC5):c.2836G>T (p.Gly946Ter) | BIVM-ERCC5 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 41495 | NM_000123.4(ERCC5):c.83C>A (p.Ala28Asp) | BIVM-ERCC5 | Pathogenic | no assertion criteria provided |
| 41496 | NM_000123.4(ERCC5):c.2904G>C (p.Trp968Cys) | BIVM-ERCC5 | Pathogenic | no assertion criteria provided |
| 517221 | NM_000123.4(ERCC5):c.1173dup (p.Lys392Ter) | BIVM-ERCC5 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 802997 | NM_000123.4(ERCC5):c.840_841dup (p.Val281fs) | BIVM-ERCC5 | Pathogenic | criteria provided, single submitter |
| 16567 | NM_000123.4(ERCC5):c.2375C>T (p.Ala792Val) | BIVM-ERCC5 | Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 2443988 | NM_000123.4(ERCC5):c.381-2A>G | BIVM-ERCC5 | Likely pathogenic | no assertion criteria provided |
| 2627959 | NM_000123.4(ERCC5):c.323del (p.Lys108fs) | BIVM-ERCC5 | Likely pathogenic | criteria provided, single submitter |
| 3068061 | NM_000123.4(ERCC5):c.2941_2944del (p.Leu981fs) | BIVM-ERCC5 | Likely pathogenic | criteria provided, single submitter |
| 3382284 | NM_000123.4(ERCC5):c.265-2A>G | BIVM-ERCC5 | Likely pathogenic | criteria provided, single submitter |
| 3391244 | NM_000123.4(ERCC5):c.136del (p.His46fs) | BIVM-ERCC5 | Likely pathogenic | criteria provided, single submitter |
| 3575646 | NM_000123.4(ERCC5):c.265-1G>T | BIVM-ERCC5 | Likely pathogenic | criteria provided, single submitter |
| 3575648 | NM_000123.4(ERCC5):c.812del (p.Gly271fs) | BIVM-ERCC5 | Likely pathogenic | criteria provided, single submitter |
| 3575649 | NM_000123.4(ERCC5):c.897del (p.Val300fs) | BIVM-ERCC5 | Likely pathogenic | criteria provided, single submitter |
| 3575651 | NM_000123.4(ERCC5):c.1160_1183delinsA (p.Thr387fs) | BIVM-ERCC5 | Likely pathogenic | criteria provided, single submitter |
| 3575653 | NM_000123.4(ERCC5):c.1463dup (p.Ser489fs) | BIVM-ERCC5 | Likely pathogenic | criteria provided, single submitter |
| 3575655 | NM_000123.4(ERCC5):c.1924G>T (p.Glu642Ter) | BIVM-ERCC5 | Likely pathogenic | criteria provided, single submitter |
| 3575658 | NM_000123.4(ERCC5):c.2431del (p.Ser811fs) | BIVM-ERCC5 | Likely pathogenic | criteria provided, single submitter |
| 3575660 | NM_000123.4(ERCC5):c.2533G>T (p.Gly845Ter) | BIVM-ERCC5 | Likely pathogenic | criteria provided, single submitter |
| 522358 | NM_000123.4(ERCC5):c.2353C>T (p.Gln785Ter) | BIVM-ERCC5 | Likely pathogenic | criteria provided, single submitter |
| 1252023 | NM_000123.4(ERCC5):c.2392G>T (p.Asp798Tyr) | BIVM-ERCC5 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 11 · Orphanet: 3 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
GenCC gene–disease validity (cohort genes)
the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.
| Gene | Classification | Inheritance | Disease | Records |
|---|---|---|---|---|
| ERCC5 | Definitive | Autosomal recessive | xeroderma pigmentosum group G | 11 |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| ERCC5 | Orphanet:1466 | COFS syndrome |
| ERCC5 | Orphanet:220295 | Xeroderma pigmentosum-Cockayne syndrome complex |
| ERCC5 | Orphanet:910 | Xeroderma pigmentosum |
Cohort genes → proteins
2 cohort genes, 1 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 2 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| ERCC5 | HGNC:3437 | ENSG00000134899 | P28715 | DNA excision repair protein ERCC-5 | gencc |
| BIVM-ERCC5 | HGNC:43690 | ENSG00000270181 | BIVM-ERCC5 readthrough | clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| ERCC5 | DNA excision repair protein ERCC-5 | Single-stranded structure-specific DNA endonuclease involved in DNA excision repair. |
Protein-family classification
Druggable: 0 · Difficult: 0 · Unknown: 2 · Druggable fraction: 0.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Other/Unknown | 2 | 1.8× | 0.312 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| ERCC5 | Other/Unknown | no | XPG/Rad2_eukaryotes, XPG/Rad2, XPG_DNA_repair_N | |
| BIVM-ERCC5 | Other/Unknown | no |
Expression context
Cohort genes with no expression data: 0.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 2 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| body of pancreas | 1 |
| calcaneal tendon | 1 |
| granulocyte | 1 |
| male germ line stem cell (sensu Vertebrata) in testis | 1 |
| tonsil | 1 |
| ventricular zone | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| ERCC5 | 166 | ubiquitous | yes | granulocyte, calcaneal tendon, body of pancreas |
| BIVM-ERCC5 | 108 | ubiquitous | yes | male germ line stem cell (sensu Vertebrata) in testis, tonsil, ventricular zone |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| ERCC5 | 2,749 |
| BIVM-ERCC5 | 0 |
Structural data
PDB: 1 · AlphaFold-only: 0 · No structure: 1
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| ERCC5 | P28715 | 10 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 3. Enrichment computed across 2 evidence-associated genes (1 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| Dual Incision in GG-NER | 1 | 259.6× | 0.006 | ERCC5 |
| Formation of Incision Complex in GG-NER | 1 | 253.8× | 0.006 | ERCC5 |
| Dual incision in TC-NER | 1 | 173.0× | 0.006 | ERCC5 |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| base-excision repair, AP site formation | 1 | 3370.4× | 0.002 | ERCC5 |
| response to UV-C | 1 | 1685.2× | 0.002 | ERCC5 |
| transcription-coupled nucleotide-excision repair | 1 | 1203.7× | 0.002 | ERCC5 |
| nucleotide-excision repair | 1 | 383.0× | 0.004 | ERCC5 |
| response to UV | 1 | 366.4× | 0.004 | ERCC5 |
| double-strand break repair via homologous recombination | 1 | 156.0× | 0.007 | ERCC5 |
| negative regulation of apoptotic process | 1 | 34.8× | 0.029 | ERCC5 |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 2
Druggability breadth: 1 of 2 evidence-associated genes (50%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| ERCC5 | 0 | 0 |
| BIVM-ERCC5 | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 0.
Cohort genes with ChEMBL bioactivity (full, sorted by assay count)
| Symbol | Assays | Type breakdown |
|---|---|---|
| ERCC5 | 3 | Binding:3 |
Pharmacogenomics
Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 2 | ERCC5, BIVM-ERCC5 |
Undrugged target profiles
2 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| ERCC5 | 3 | — |
| BIVM-ERCC5 | 0 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
- Cohort genes: ERCC5